Immunology

Managing the Immune Deficiency

At a Glance

Managing PLAID and APLAID involves matching infection prevention to each person’s infection history, antibody levels, and vaccine response. Options may include immunoglobulin replacement, preventive antibiotics, carefully selected vaccines, and a written fever action plan.

Managing the immune deficiency in PLAID and APLAID requires a careful balancing act. Because the PLCG2 gene is essential for B cells to produce protective antibodies, many patients have a “primary antibody deficiency” that makes them more susceptible to bacterial infections, particularly in the sinuses, ears, and lungs (sinopulmonary infections) ^[1]^[2].

Understanding the Risk of Infection

In these conditions, the body may not produce enough immunoglobulins (antibodies like IgG, IgA, and IgM) or may fail to remember how to fight specific germs even after being vaccinated ^[1]^[3]. This leads to:

Recurrent ear and sinus infections.
Pneumonia, which can cause long-term lung damage called bronchiectasis if recurrent or not controlled ^[4]^[5].
Infections that are resistant, require prolonged treatment, or represent an inadequate response rather than simply an “antibiotic failure.”

Immunoglobulin Replacement Therapy (IgRT)

If your immune system cannot make enough functional antibodies, doctors can “replace” them using products collected from healthy donors. This therapy is called IgRT ^[4].

The decision to start IgRT is not based on your genetic diagnosis alone. Instead, your doctor will look at several factors:

Infection History: Have you had severe infections, hospitalizations, or several rounds of antibiotics in the last year? ^[5]
Antibody Levels: Are your overall IgG levels or specific functional antibodies significantly low? ^[6]
Vaccine Response: Did your body fail to make a “protective” level of antibodies after a routine shot (like the pneumonia vaccine)? ^[5]^[7]

Two Ways to Receive IgRT

There are two main delivery methods, and the choice is often based on your lifestyle and preference:

IVIG (Intravenous): Administered into a vein, usually in a clinic or hospital once every 3 to 4 weeks ^[8].
SCIG (Subcutaneous): Administered under the skin, often at home using a small pump or “rapid push” method, usually once a week ^[9]. This method often results in fewer “ups and downs” in antibody levels and has fewer systemic side effects ^[9].

Doctors typically evaluate an IgRT trial over 6 to 12 months to see if it significantly reduces the number and severity of your infections ^[5]^[10].

Prophylactic Antibiotics

Sometimes, your doctor may prescribe prophylactic antibiotics—low doses of antibiotics taken daily to prevent infections before they start ^[11]^[12]. There is no automatic escalation rule. The choice between daily antibiotics and IgRT depends heavily on documenting the specific infections and organisms, your vaccine responses, your immunoglobulin levels, the presence of bronchiectasis or other structural disease, antibiotic tolerance, and resistance risk ^[12]^[13].

Vaccination Guidelines

Vaccines are still an important part of care, but the rules are nuanced for people with antibody deficiencies:

Inactivated (Non-Live) Vaccines: These include the flu shot and the pneumonia vaccine. They are generally safe and recommended ^[14]. Even if your body doesn’t make a perfect antibody response, some protection is better than none ^[15].
Live Attenuated Vaccines: These include the MMR (Measles, Mumps, Rubella) and Varicella (chickenpox) vaccines. These contain a weakened but living virus. Do not assume these are universally forbidden, and do not self-regulate. The decision requires individualized immunologist guidance. Your eligibility depends on your T-cell/combined immune function, the specific immune defect, current immunosuppressive drugs and doses, age, and your immunoglobulin-replacement timing ^[16]^[17].

The Balancing Act

If you have APLAID, you may need medications (like steroids or biologics) to calm down autoinflammation (inappropriate innate immune activation). However, these same drugs can further weaken your ability to fight off germs ^[18].
Your medical team must implement drug-specific monitoring and infection-prevention advice, including screening before selected biologics. The effects differ substantially by drug; steroids and biologics should not be treated as having the exact same effect on your IgG or infection risk. Never start or stop antibiotics or immunosuppressants yourself ^[19]^[20]. Work with your team to create a written fever and infection action plan indicating exactly when to seek emergency evaluation.

Common questions in this guide

Why are people with PLAID or APLAID more prone to infections?

PLCG2 helps B cells make protective antibodies. In PLAID and APLAID, antibody levels or the ability to make antibodies against specific germs may be reduced, leading to repeated ear, sinus, and lung infections.

When is immunoglobulin replacement therapy considered for PLAID or APLAID?

Doctors consider IgRT when a person has serious or repeated infections, low overall or specific antibody levels, or a poor response to vaccines. The genetic diagnosis alone does not determine treatment, and the team may assess whether a 6- to 12-month trial reduces infections.

What is the difference between IVIG and SCIG for antibody deficiency?

IVIG is given into a vein in a clinic or hospital, usually every 3 to 4 weeks. SCIG is given under the skin, often at home each week; it can provide steadier antibody levels and fewer body-wide side effects, but the best option depends on the person’s needs and preferences.

Can preventive antibiotics be used instead of immunoglobulin therapy?

Daily preventive antibiotics may help some people avoid infections, but there is no single rule for choosing them over IgRT. The decision considers infection history and organisms, vaccine responses, antibody levels, lung damage such as bronchiectasis, antibiotic tolerance, and resistance risk.

Are live vaccines safe for someone with PLAID or APLAID?

Inactivated vaccines, such as flu and pneumonia vaccines, are generally safe and recommended for people with antibody deficiencies. Live vaccines such as MMR and chickenpox vaccine are not automatically forbidden or automatically safe; an immunologist must review immune function, medicines, age, and the timing of immunoglobulin therapy.

How do steroids and biologic medicines affect infection risk in APLAID?

Steroids and biologic medicines may calm the inflammation in APLAID, but they can also weaken protection against infections. Their effects are not identical, so the care team should provide drug-specific monitoring, screening when needed, and a written plan for fever or infection; do not start or stop them without medical advice.

Get notified when new evidence is published on PLCG2-associated antibody deficiency and immune dysregulation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.
Martín-Nalda A, Fortuny C, Rey L, et al.
Journal of clinical immunology 2020; (40(7)):987-1000 doi:10.1007/s10875-020-00794-7.
PMID: 32671674
2
Case Report: A Rare Case of Autoinflammatory Phospholipase Cγ2 (PLCγ2)-Associated Antibody Deficiency and Immune Dysregulation Complicated With Gangrenous Pyoderma and Literature Review.
Wu N, Zhang B, Wang T, et al.
Frontiers in immunology 2021; (12()):667430 doi:10.3389/fimmu.2021.667430.
PMID: 34093563
3
Value of diagnostic vaccination in diagnosis of humoral inborn errors of immunity.
Hlongwa L, Peter J, Mayne E
Human immunology 2023; (84(5-7)):337-341 doi:10.1016/j.humimm.2023.04.004.
PMID: 37080873
4
Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.
Pecoraro A, Crescenzi L, Granata F, et al.
International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.
PMID: 28898770
5
Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
Edgar JDM, Richter AG, Huissoon AP, et al.
Journal of clinical immunology 2018; (38(2)):204-213 doi:10.1007/s10875-017-0469-4.
PMID: 29423883
6
When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S, Chapel H, Litzman J
Clinical and experimental immunology 2017; (188(3)):333-341 doi:10.1111/cei.12915.
PMID: 28000208
7
Specific Antibody Deficiency in Adult Patients With IgG or IgG Subclass Deficiency.
Kim JH, Jang JH, Lee SH, et al.
Allergy, asthma & immunology research 2021; (13(2)):271-283 doi:10.4168/aair.2021.13.2.271.
PMID: 33474861
8
Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy and asthma proceedings 2016; (37(6)):426-431 doi:10.2500/aap.2016.37.3987.
PMID: 27931296
9
A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
Epland K, Suez D, Paris K
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):87 doi:10.1186/s13223-022-00726-7.
PMID: 36180928
10
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
Grigoriadou S, Clubbe R, Garcez T, et al.
Clinical and experimental immunology 2022; (210(1)):1-13 doi:10.1093/cei/uxac070.
PMID: 35924867
11
Primary Immunodeficiency: Specific antibody deficiency with normal IgG.
Hatcher VR, Alix VC, Hellu TS, Schuldt MM
Allergy and asthma proceedings 2024; (45(5)):321-325 doi:10.2500/aap.2024.45.240057.
PMID: 39294904
12
Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency.
Smits BM, Kleine Budde I, de Vries E, et al.
Journal of clinical immunology 2021; (41(2)):382-392 doi:10.1007/s10875-020-00841-3.
PMID: 33206257
13
Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency.
Joud Hajjar , Nguyen AL, Constantine G, et al.
Journal of clinical immunology 2020; (40(1)):158-164 doi:10.1007/s10875-019-00716-2.
PMID: 31758281
14
Vaccination in PADs.
Milito C, Soccodato V, Collalti G, et al.
Vaccines 2021; (9(6)) doi:10.3390/vaccines9060626.
PMID: 34207916
15
Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).
Mieves JF, Wittke K, Freitag H, et al.
Current allergy and asthma reports 2017; (17(11)):78 doi:10.1007/s11882-017-0749-3.
PMID: 28983790
16
Vaccination in Primary Immunodeficiency Disorders.
Sobh A, Bonilla FA
The journal of allergy and clinical immunology. In practice 2016; (4(6)):1066-1075 doi:10.1016/j.jaip.2016.09.012.
PMID: 27836056
17
Current Vaccination Principles and Practices in Adult Cancer Patients.
Elik DB, Kıvrak EE, Yıldırım HÇ, et al.
Journal of clinical practice and research 2026; (48(3)):226-234 doi:10.14744/cpr.2026.02998.
PMID: 42416124
18
Immunosuppression in Patients With Primary Immunodeficiency-Walking the Line.
Mustafa SS, Rider NL, Jolles S
The journal of allergy and clinical immunology. In practice 2022; (10(12)):3088-3096 doi:10.1016/j.jaip.2022.08.025.
PMID: 36049628
19
[Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency].
Hanitsch LG
Der Internist 2022; (63(5)):484-492 doi:10.1007/s00108-022-01326-8.
PMID: 35412057
20
Secondary antibody deficiencies.
Dhalla F, Misbah SA
Current opinion in allergy and clinical immunology 2015; (15(6)):505-13 doi:10.1097/ACI.0000000000000215.
PMID: 26406183

This page explains infection prevention and immune-deficiency treatments for PLAID and APLAID for informational purposes only and does not constitute medical advice. An immunologist should individualize vaccines, antibiotics, and immunoglobulin therapy for you or your child.

Guide Contents